Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients

被引：0
|
作者：
Borlenghi, E. [1 ]
Roccaro, A. M. [2 ]
Cattaneo, C. [1 ,3 ]
机构：
[1] ASST Spedali Civili, Hematol, Brescia, Italy
[2] ASST Spedali Civili, Translat Res & Phase Unit 1, Clin Trial Ctr, Brescia, Italy
[3] ASST Spedali Civili, Hematol, I-25123 Brescia, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 203卷 / 04期
关键词：
acute myeloid leukaemia; invasive fungal infections; myelodysplastic syndromes; posaconazole; venetoclax;
D O I：
10.1111/bjh.19138
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Invasive fungal infections (IFIs), mainly due to pulmonary aspergillosis, are considered a serious complication in acute leukaemia, with an unfavourable impact on patient. In this well-conducted retrospective study, Reynolds et al. suggest that the use of posaconazole prophylaxis in association with venetoclax plus hypomethylating agents or chemotherapy leads to a reduction of IFI incidence. Therapeutic drug monitoring of posaconazole levels is suggested, even if no correlation with IFI risk has been demonstrated.
引用
收藏
页码：504 / 506
页数：3
相关论文
共 50 条
  • [21] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [22] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [23] Effects of CYP3A5 polymorphism and renal impairment on the drug interaction between venetoclax and fluconazole in acute myeloid leukaemia patients
    Kobayashi, Takahiro
    Sato, Honami
    Akamine, Yumiko
    Fukushi, Yayoi
    Takahashi, Naoto
    Miura, Masatomo
    XENOBIOTICA, 2025, 55 (01) : 37 - 42
  • [24] Venetoclax plus '2+5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis
    Wang, Huafeng
    Yao, Yiyi
    Mao, Liping
    Lou, Yinjun
    Ren, Yanling
    Ye, Xingnong
    Yang, Min
    Ma, Liya
    Zhang, Yi
    Zhou, Yile
    Wu, Jiaying
    Huang, Xin
    Wang, Yungui
    Xu, Huan
    Tong, Hongyan
    Zhu, Hong-Hu
    Jin, Jie
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 568 - 572
  • [25] Outpatient initiation of venetoclax in patients with acute myeloid leukemia
    Palmer, Shannon
    Patel, Anand
    Wang, Christopher
    Patel, Bianka
    Zeidner, Joshua
    Foster, Matthew
    Muluneh, Benyam
    Buhlinger, Kaitlyn
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1590 - 1598
  • [26] Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy
    Yang, Yi-Tsung
    Yao, Chi-Yuan
    Kao, Chein-Jun
    Chiu, Po-Ju
    Lin, Ming-En
    Hou, Hsin-An
    Lin, Chien-Chin
    Chou, Wen-Chien
    Tien, Hwei-Fang
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1751 - 1764
  • [27] Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
    Fiedler, Walter
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1135 - 1136
  • [28] Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
    De Gregori, Simona
    Gelli, Eleonora
    Capone, Mara
    Gambini, Giulia
    Roncoroni, Elisa
    Rossi, Marianna
    Cabrera, Claudia Patricia Tobar
    Martini, Gianluca
    Calabretta, Ludovica
    Arcaini, Luca
    Albertini, Riccardo
    Zappasodi, Patrizia
    PHARMACEUTICS, 2023, 15 (06)
  • [29] Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage
    Tinajero, Jose
    Ngo, Dat
    Lee, Brian
    Kim, Hoim
    Aldoss, Ibrahim
    Ball, Brian
    Koller, Paul
    Arslan, Shukaib
    Pourhassan, Hoda
    Otoukesh, Salman
    Al Malki, Monzr
    Stein, Anthony
    Nakamura, Ryotaro
    Sandhu, Karamjeet
    Blackmon, Amanda
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S298 - S299
  • [30] Real-World Experience with Venetoclax-Based Regimens for the Treatment of Acute Myeloid Leukemia
    Ceparano, Giusy
    Sciume, Mariarita
    Fabris, Sonia
    Barozzi, Enrico
    Rampi, Nicolo
    De Roberto, Pasquale
    Baldini, Luca
    Fracchiolla, Nicola Stefano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S298 - S298
12345